Clinical Trial Results:
            A 14 day monocentric, double-blind, randomized phase III clinical study to investigate the antimicrobial efficacy and local tolerability of an antiseptic mouth rinse solution (Stellisept mucosa, containing 0.1 % octenidine dihydrochloride)with  daily applications in comparison to a reference product (Octenisept®) in a panel of 44 healthy male and female volunteers
    
|     Summary | |
|     EudraCT number | 2006-000062-37 | 
|     Trial protocol | DE | 
|     Global completion date | 
                                    19 Jun 2006
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    23 Jun 2022
                             | 
|     First version publication date | 
                                    23 Jun 2022
                             | 
|     Other versions | |
|     Summary report(s) | 2006-000062-37 Stellisept mucosa | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
